11.4 Trillion Won Flooded Into Samsung Biologics' Paid-in Public Offering
4 Articles
4 Articles
Samsung Biologics attracted subscription deposits exceeding 11 trillion won in its public offering for a paid-in capital increase, conducted to raise funds for the acquisition of a Swiss company that produces peptides, which are active ingredients for obesity treatments. The competition ratio was 135.6 to 1, meaning a deposit of 160 million won was required to be allocated just one share. On the 16th, Samsung Biologics [announced] 2.7 trillion
(Seoul = Yonhap News) Reporter Park Sang-hyun = Samsung Biologics [207940] saw over 11 trillion won in funds flock to the general public offering subscription for its paid-in capital increase held on the 12th and 13th...
Samsung Biologics has concluded subscriptions for a paid-in capital increase worth approximately 2.7 trillion won. With over 11.4 trillion won in subscription deposits pouring into the general offering, it set an all-time record for a paid-in capital increase conducted via a shareholder allocation followed by a public offering of unsubscribed shares. The funds raised will be used to acquire Polypeptide Group, a global peptide drug contract devel…
Samsung Biologics Rights Offering Draws 11.44 Trillion Won in Subscription Deposits
Samsung Biologics’ Plant 4 in Yeonsu-gu, Incheon. Samsung Biologics’ general public offering for its 2.7-trillion-won, or approximately $2.02 billion, rights offering attracted more than 11 trillion won in subscription deposits, demonstrating strong market demand. The result marks the largest amount on record among rights offerings that proceeded to a general public subscription phase following a shareholder allocation round. According to the Fi…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium







